Lv2
200 积分 2025-01-17 加入
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study
20天前
已完结
Low-dose chemotherapy remodels hepatic immune landscape and potentiates anti-tumor response to immune checkpoint blockade in cholangiocarcinoma
23天前
已完结
Intrahepatic arterial infusion of chemotherapy: Pharmacologic principles
1个月前
已完结
PD-1/PD-L1 blockade therapy in hepatocellular carcinoma: Current status and potential biomarkers
1个月前
已完结
[Consensus on the management of liver injury associated with targeted drugs and immune checkpoint inhibitors for hepatocellular carcinoma ( version 2024)]
1个月前
已完结
Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus Immunotherapy and targeted therapy in HCC
5个月前
已完结
Prognostic Impact and Predictive Model for Early Non-curative Recurrence After Liver Resection for Hepatocellular Carcinoma: a Retrospective Cohort Study
6个月前
已关闭
Contemporary clinical trials in pancreatic cancer immunotherapy targeting PD-1 and PD-L1
7个月前
已完结
Abc-06: a Randomised Phase Iii, Multi-Centre, Open-Label Study of Active Symptom Control (Asc) Alone or Asc with Oxaliplatin / 5-Fu Chemotherapy for Patients with Locally Advanced / Metastatic Biliary Tract Cancers (Abc) Previously Treated with Cisplatin / Gemcitabine Chemotherapy
8个月前
已关闭
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
8个月前
已完结
皖公网安备34019202002308
